Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Third Party VSTs for Viral Infections in Immunocompromised Patients
NCT02532452Phase 2Recruiting
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Sep 2015
- Primary completion
- Dec 2028
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of short-term expanded virus-specific T-cells (St. Anna Kinderkrebsforschung) in viral infection, sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoints: Successful production of viral specific T-cells at 30 days, Percentage of patients who do not have infusional toxicity at 30 minutes and 1 more. Started Sep 2015; status: recruiting.
02
Drugs
short-term expanded virus-specific T-cells (St. Anna Kinderkrebsforschung)
03
Conditions
viral infection
Beyond the preview
Go deeper on NCT02532452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02532452.